Latest Ovarian Cancer News

Page 2 of 4
Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.
Ada Torres
Ada Torres
7 Oct 2025
Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.
Ada Torres
Ada Torres
29 Sept 2025
INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.
Ada Torres
Ada Torres
26 Sept 2025
BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.
Ada Torres
Ada Torres
18 Sept 2025
Cleo Diagnostics has received encouraging feedback from the U.S. FDA on its ovarian cancer pre-surgical triage test, reinforcing its clinical trial design and regulatory strategy ahead of a critical 510(k) submission.
Ada Torres
Ada Torres
15 Sept 2025
Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.
Ada Torres
Ada Torres
26 Aug 2025
Amplia Therapeutics has successfully raised A$2.65 million through its Share Purchase Plan, exceeding expectations and bolstering funding for pivotal clinical trials of its lead drug narmafotinib.
Ada Torres
Ada Torres
26 Aug 2025
INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.
Ada Torres
Ada Torres
22 Aug 2025
Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.
Ada Torres
Ada Torres
18 Aug 2025
Imagion Biosystems has raised A$3.5 million through a placement to fund its Phase 2 clinical trial for HER2+ Breast Cancer in the US, marking a significant step in advancing its proprietary MagSense® imaging technology.
Ada Torres
Ada Torres
4 Aug 2025
INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.
Ada Torres
Ada Torres
31 July 2025
Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.
Ada Torres
Ada Torres
29 July 2025